Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below 50-Day Moving Average - Should You Sell?

Key Points

• Price dipped below key technical level: FRX traded as low as C$8.70, dropping beneath its 50‑day moving average of C$10.66 (200‑day C$11.21), with a market cap of C$297.22M and a beta of 3.01.
• Analyst sentiment is bullish: B. Riley upgraded Fennec to a "Strong Buy" and MarketBeat lists the company's consensus rating as "Strong Buy."
• Insider activity: Director Rostislav Raykov sold 10,349 shares at an average C$10.69 on Feb 2, slightly reducing his stake while corporate insiders collectively own 16.20% of the company.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$10.66 and traded as low as C$8.70. Fennec Pharmaceuticals shares last traded at C$8.70, with a volume of 169 shares.

Wall Street Analyst Weigh In

Separately, B. Riley Financial raised Fennec Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Strong Buy".

Fennec Pharmaceuticals Price Performance

The stock has a market capitalization of C$297.22 million, a P/E ratio of -24.86 and a beta of 3.01. The stock has a fifty day moving average price of C$10.66 and a 200 day moving average price of C$11.21.

Insider Buying and Selling at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov sold 10,349 shares of the company's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of C$10.69, for a total transaction of C$110,630.81. Following the sale, the director directly owned 2,709,294 shares in the company, valued at C$28,962,352.86. This represents a 0.38% decrease in their ownership of the stock. 16.20% of the stock is currently owned by corporate insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.